Evidence map›Paper›PMID 35248422›Full record

ReviewVaccine2022

WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations.

Jerome Amir Singh, Sonali Kochhar, Jonathan Wolff, Caesar Atuire, Anant Bhan, Ezekiel Emanuel, Ruth Faden, Prakash Ghimire, Dirceu Greco, Calvin Ho and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. How can we make sound replication decisions?Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. FcFrontiers in cardiovascular medicine · 2023
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jerome Amir SinghHoward College School of Law, University of KwaZulu-Natal, Durban, South Africa; Scientific Advisory Group on Emergencies (SAGE), Academy of Science of South Africa (ASSAf), Pretoria, South Africa; Department of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. Electronic address: singhj9@ukzn.ac.za.
Sonali KochharDepartment of Global Health, University of Washington, Seattle, WA, USA; Global Healthcare Consulting, Delhi, India.
Jonathan WolffBlavatnik School of Government, University of Oxford, Oxford, UK.
Caesar AtuireDepartment of Philosophy and Classics, University of Ghana, Accra, Ghana.
Anant BhanDepartment of Community Medicine and Centre for Ethics, Yenepoya University, Mangalore, India.
Ezekiel EmanuelGlobal Initiatives and Healthcare Transformation Institute, University of Pennsylvania, Philadelphia, PA, USA.
Ruth FadenJohns Hopkins Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
Prakash GhimireTribhuvan University, Kirtipur, Nepal.
Dirceu GrecoSchool of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Calvin HoFaculty of Law and Centre for Medical Ethics, University of Hong Kong, Hong Kong Special Administrative Region, China.
Suerie MoonInternational Relations and Political Science Department & Interdisciplinary Programmes, Global Health Centre, Graduate Institute of International and Development Studies, Geneva, Switzerland.
Ehsan Shamsi-GooshkiDepartment of Medical Ethics, Tehran University of Medical Sciences, Tehran, Iran.
Aissatou TouréInstitut Pasteur, Dakar, Senegal.
Beatriz ThoméDepartamento de Medicina Preventiva, Universidade Federal de São Paulo, Rua Botucatu,Sao Paolo, Brazil.
Maxwell J SmithFaculty of Health Sciences, Western University, London, Ontario, Canada.
Ross E G UpshurDepartment of Family and Community Medicine and Dalla Lana School of Public Health University of Toronto, Toronto, Ontario, Canada.

Funding

Wellcome Trust
6 · The paper itself

Abstract

While the degree of COVID-19 vaccine accessibility and uptake varies at both national and global levels, increasing vaccination coverage raises questions regarding the standard of prevention that ought to apply to different settings where COVID-19 vaccine trials are hosted. A WHO Expert Group has developed guidance on the ethical implications of conducting placebo-controlled trials in the context of expanding global COVID-19 vaccine coverage. The guidance also considers alternative trial designs to placebo controlled trials in the context of prototype vaccines, modified vaccines, and next generation vaccines.

Indexed as

COVID-19VaccinesCOVID-19 VaccinesHumansSARS-CoV-2World Health OrganizationCOVID-19 VaccinesVaccinesPlacebo-controlled trialsResearch ethicsStandard of careStandard of preventionTrial designs

Identifiers

PMID35248422
PMCPMC8882397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.